Loading clinical trials...

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms | Clinical Trials | Clareo Health

RECRUITINGNA

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

HEARS Neuropsychiatric Symptoms & Hearing Loss: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

NCT06930560•Johns Hopkins University

View on ClinicalTrials.gov

Summary

This randomized controlled trial study aims to evaluate a revised hearing care intervention for older adults with Alzheimer's Disease and Related Dementias (ADRD). The community-delivered hearing care intervention utilizes tailored strategies to assess impact on communication, neuropsychiatric symptoms (NPS), and care partner distress.

Eligibility

Age

60 - 100 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age 60 - 100 years old
•English-speaking
•Diagnosis of probable Alzheimer's Disease or other related dementia according to the core clinical criteria outlined in the National Institute on Aging (NIA) and Alzheimer's Association Guidelines
•Speech frequency pure tone average (0.5- 4 kHz) \>25 db in the better-hearing ear; adult onset hearing loss
•Availability of caregiver/study partner who is 18+ to participate in all study-related visits and who provides care supervision
•Stable (for 2 weeks or longer) dosing of medication (e.g. antidepressants, antipsychotics) for neuropsychiatric symptoms

Exclusion Criteria

•Current self-reported use of hearing aid or amplification device
•Medical contraindication to use hearing aids ( e.g. draining ears)
•Inability to participate in the 1-month follow up

Locations (1)

Johns Hopkins Memory and Alzheimer's Treatment Center

Baltimore, Maryland, United States

Key Dates

Start Date

October 15, 2025

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2027

Last Updated

November 24, 2025

Enrollment

300

ESTIMATED participants

Conditions

Alzheimer DiseaseDementiaHearing LossCognitive Impairment

Interventions

HEARS-NPS device

DEVICE

HEARS-NPS program

BEHAVIORAL

Contacts

Esther Oh, MD, Ph.D.

CONTACT

410-550-0925 eoh9@jhmi.edu

Jami Trumbo, MSPH

CONTACT

jami.trumbo@jhu.edu

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

[18F]F-DOPA Imaging in Patients With Autonomic Failure

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Testing the Pain Clinical Practice Guideline